Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.

Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, Idbaih A.

J Neurooncol. 2019 Aug;144(1):33-41. doi: 10.1007/s11060-019-03204-0. Epub 2019 Jun 13.

PMID:
31197598
2.

A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.

Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, Daniau M, Nadaradjane A, Gleize V, Paris S, Marie Y, Giry M, Polivka M, Figarella-Branger D, Aubriot-Lorton MH, Villa C, Vasiljevic A, Lechapt-Zalcman E, Kalamarides M, Sharif A, Mokhtari K, Pagnotta SM, Iavarone A, Lasorella A, Huillard E, Sanson M.

Nat Commun. 2018 Jun 18;9(1):2371. doi: 10.1038/s41467-018-04622-w.

3.

Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions.

Perreault M, Wunsch E, Białek A, Trottier J, Verreault M, Caron P, Poirier GG, Milkiewicz P, Barbier O.

Can J Gastroenterol Hepatol. 2018 Apr 11;2018:8096314. doi: 10.1155/2018/8096314. eCollection 2018.

4.

N-3 Polyunsaturated Fatty Acids Stimulate Bile Acid Detoxification in Human Cell Models.

Cieślak A, Trottier J, Verreault M, Milkiewicz P, Vohl MC, Barbier O.

Can J Gastroenterol Hepatol. 2018 Apr 5;2018:6031074. doi: 10.1155/2018/6031074. eCollection 2018.

5.

Correction to: ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):487. doi: 10.1007/s11060-018-2830-8.

PMID:
29549621
6.

ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.

Dréan A, Rosenberg S, Lejeune FX, Goli L, Nadaradjane AA, Guehennec J, Schmitt C, Verreault M, Bielle F, Mokhtari K, Sanson M, Carpentier A, Delattre JY, Idbaih A.

J Neurooncol. 2018 Jul;138(3):479-486. doi: 10.1007/s11060-018-2819-3. Epub 2018 Mar 8. Erratum in: J Neurooncol. 2018 Mar 16;:.

PMID:
29520610
7.

A driver role for GABA metabolism in controlling stem and proliferative cell state through GHB production in glioma.

El-Habr EA, Dubois LG, Burel-Vandenbos F, Bogeas A, Lipecka J, Turchi L, Lejeune FX, Coehlo PL, Yamaki T, Wittmann BM, Fareh M, Mahfoudhi E, Janin M, Narayanan A, Morvan-Dubois G, Schmitt C, Verreault M, Oliver L, Sharif A, Pallud J, Devaux B, Puget S, Korkolopoulou P, Varlet P, Ottolenghi C, Plo I, Moura-Neto V, Virolle T, Chneiweiss H, Junier MP.

Acta Neuropathol. 2017 Apr;133(4):645-660. doi: 10.1007/s00401-016-1659-5. Epub 2016 Dec 28.

8.

UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling.

Li H, Xie N, Chen R, Verreault M, Fazli L, Gleave ME, Barbier O, Dong X.

Cancer Res. 2016 Nov 15;76(22):6701-6711. doi: 10.1158/0008-5472.CAN-16-1518. Epub 2016 Sep 22.

9.

Selective and sensitive quantification of the cytochrome P450 3A4 protein in human liver homogenates through multiple reaction monitoring mass spectrometry.

Cieślak A, Kelly I, Trottier J, Verreault M, Wunsch E, Milkiewicz P, Poirier G, Droit A, Barbier O.

Proteomics. 2016 Nov;16(21):2827-2837. doi: 10.1002/pmic.201500386. Epub 2016 Oct 10.

PMID:
27634100
10.

Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors.

Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, Marie Y, Bielle F, Mokhtari K, Hoang-Xuan K, Ligon K, Sanson M, Delattre JY, Idbaih A.

Neuro Oncol. 2017 Feb 1;19(2):219-228. doi: 10.1093/neuonc/now160.

11.

Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.

Dréan A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, Delattre JY, Carpentier A, Idbaih A.

Expert Rev Neurother. 2016 Nov;16(11):1285-1300. Epub 2016 Jul 4. Review. Erratum in: Expert Rev Neurother. 2016 Nov;16(11):iv.

PMID:
27310463
12.

A surveillance tool to assess diets according to Eating Well with Canada's Food Guide.

Elvidge Munene LA, Dumais L, Esslinger K, Jones-Mclean E, Mansfield E, Verreault MF, Villeneuve M, Miller D, St-Pierre S.

Health Rep. 2015 Nov;26(11):12-20.

13.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2015 Dec 28;220(Pt A):348-357. doi: 10.1016/j.jconrel.2015.10.053. Epub 2015 Nov 1.

PMID:
26528901
14.

Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, Guehennec J, Knoff D, Labussière M, Marie Y, Ligon AH, Mokhtari K, Hoang-Xuan K, Sanson M, Alexander BM, Wen PY, Delattre JY, Ligon KL, Idbaih A.

Clin Cancer Res. 2016 Mar 1;22(5):1185-96. doi: 10.1158/1078-0432.CCR-15-1015. Epub 2015 Oct 19. Erratum in: Clin Cancer Res. 2016 May 1;22(9):2313.

15.

Comorbidity of ADHD and Anxiety Disorders in School-Age Children: Impact on Sleep and Response to a Cognitive-Behavioral Treatment.

Bériault M, Turgeon L, Labrosse M, Berthiaume C, Verreault M, Berthiaume C, Godbout R.

J Atten Disord. 2018 Mar;22(5):414-424. doi: 10.1177/1087054715605914. Epub 2015 Sep 22.

PMID:
26396144
16.

PPARα: A Master Regulator of Bilirubin Homeostasis.

Bigo C, Kaeding J, El Husseini D, Rudkowska I, Verreault M, Vohl MC, Barbier O.

PPAR Res. 2014;2014:747014. doi: 10.1155/2014/747014. Epub 2014 Jul 23.

17.

Role of glucuronidation for hepatic detoxification and urinary elimination of toxic bile acids during biliary obstruction.

Perreault M, Białek A, Trottier J, Verreault M, Caron P, Milkiewicz P, Barbier O.

PLoS One. 2013 Nov 14;8(11):e80994. doi: 10.1371/journal.pone.0080994. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/ef13ed51-6848-419d-94d8-1bb62e7bcf52.

18.

Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.

Trottier J, Perreault M, Rudkowska I, Levy C, Dallaire-Theroux A, Verreault M, Caron P, Staels B, Vohl MC, Straka RJ, Barbier O.

Clin Pharmacol Ther. 2013 Oct;94(4):533-43. doi: 10.1038/clpt.2013.122. Epub 2013 Jun 12.

19.

The Human UDP-glucuronosyltransferase UGT2A1 and UGT2A2 enzymes are highly active in bile acid glucuronidation.

Perreault M, Gauthier-Landry L, Trottier J, Verreault M, Caron P, Finel M, Barbier O.

Drug Metab Dispos. 2013 Sep;41(9):1616-20. doi: 10.1124/dmd.113.052613. Epub 2013 Jun 11.

20.

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.

Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D, Bally MB.

PLoS One. 2013;8(3):e59597. doi: 10.1371/journal.pone.0059597. Epub 2013 Mar 15.

21.

Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzyme.

Grosse L, Campeau AS, Caron S, Morin FA, Meunier K, Trottier J, Caron P, Verreault M, Barbier O.

Basic Clin Pharmacol Toxicol. 2013 Aug;113(2):92-102. doi: 10.1111/bcpt.12071. Epub 2013 May 20.

22.

[Adult diffuse glioma: genetic heterogeneity and therapeutic implications].

Verreault M, Delattre JY, Idbaih A.

Med Sci (Paris). 2012 Oct;28(10):813-6. doi: 10.1051/medsci/20122810005. Epub 2012 Oct 12. French. No abstract available.

23.

Assessment of personality organization in couple relationships: factorial structure of the inventory of personality organization and incremental validity over neuroticism.

Verreault M, Sabourin S, Lussier Y, Normandin L, Clarkin JF.

J Pers Assess. 2013;95(1):85-95. doi: 10.1080/00223891.2012.713883. Epub 2012 Aug 20.

PMID:
22906020
24.

Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.

Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE.

Stem Cells. 2012 Jun;30(6):1064-75. doi: 10.1002/stem.1081.

25.

Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.

Pâquet S, Fazli L, Grosse L, Verreault M, Têtu B, Rennie PS, Bélanger A, Barbier O.

J Clin Endocrinol Metab. 2012 Mar;97(3):E428-32. doi: 10.1210/jc.2011-2064. Epub 2011 Dec 14.

PMID:
22170718
26.

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

Waterhouse DN, Yapp D, Verreault M, Anantha M, Sutherland B, Bally MB.

Nanomedicine (Lond). 2011 Nov;6(9):1645-54. doi: 10.2217/nnm.11.140.

PMID:
22077466
27.

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, Bally MB.

J Control Release. 2012 Feb 28;158(1):34-43. doi: 10.1016/j.jconrel.2011.09.095. Epub 2011 Oct 5.

PMID:
22001870
28.

Development of glioblastoma cell lines expressing red fluorescence for non-invasive live imaging of intracranial tumors.

Verreault M, Strutt D, Masin D, Fink D, Gill R, Bally MB.

Anticancer Res. 2011 Jun;31(6):2161-71.

PMID:
21737636
29.

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.

Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT.

BMC Cancer. 2011 Apr 8;11:124. doi: 10.1186/1471-2407-11-124.

30.

PPARalpha L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity.

Rudkowska I, Caron-Dorval D, Verreault M, Couture P, Deshaies Y, Barbier O, Vohl MC.

Mol Nutr Food Res. 2010 Apr;54(4):543-50. doi: 10.1002/mnfr.200900085.

PMID:
19937854
31.

The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.

Trottier J, El Husseini D, Perreault M, Pâquet S, Caron P, Bourassa S, Verreault M, Inaba TT, Poirier GG, Bélanger A, Guillemette C, Trauner M, Barbier O.

J Biol Chem. 2010 Jan 8;285(2):1113-21. doi: 10.1074/jbc.M109.073908. Epub 2009 Nov 4.

32.

Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential.

Verreault M, Kaeding J, Caron P, Trottier J, Grosse L, Houssin E, Pâquet S, Perreault M, Barbier O.

Drug Metab Rev. 2010 Feb;42(1):110-22. doi: 10.3109/03602530903219220. Review.

PMID:
19831728
34.

Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment.

Rudkowska I, Verreault M, Barbier O, Vohl MC.

PPAR Res. 2009;2009:369602. doi: 10.1155/2009/369602. Epub 2009 Feb 25.

35.

Lipid-activated transcription factors control bile acid glucuronidation.

Barbier O, Trottier J, Kaeding J, Caron P, Verreault M.

Mol Cell Biochem. 2009 Jun;326(1-2):3-8. doi: 10.1007/s11010-008-0001-5. Epub 2009 Jan 7. Review.

PMID:
19130183
36.

Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.

Kaeding J, Bélanger J, Caron P, Verreault M, Bélanger A, Barbier O.

Mol Cancer Ther. 2008 Feb;7(2):380-90. doi: 10.1158/1535-7163.MCT-07-0455.

37.

Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).

Edwards LA, Woo J, Huxham LA, Verreault M, Dragowska WH, Chiu G, Rajput A, Kyle AH, Kalra J, Yapp D, Yan H, Minchinton AI, Huntsman D, Daynard T, Waterhouse DN, Thiessen B, Dedhar S, Bally MB.

Mol Cancer Ther. 2008 Jan;7(1):59-70. doi: 10.1158/1535-7163.MCT-07-0329.

38.

Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.

Kaeding J, Bouchaert E, Bélanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Bélanger A, Barbier O.

Biochem J. 2008 Mar 1;410(2):245-53.

PMID:
17988216
39.

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.

Dragowska WH, Verreault M, Yapp DT, Warburton C, Edwards L, Ramsay EC, Huxham LA, Minchinton AI, Gelmon K, Bally MB.

Breast Cancer Res Treat. 2007 Dec;106(3):319-31. Epub 2007 Mar 9.

PMID:
17347776
40.

Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver.

Trottier J, Verreault M, Grepper S, Monté D, Bélanger J, Kaeding J, Caron P, Inaba TT, Barbier O.

Hepatology. 2006 Nov;44(5):1158-70.

PMID:
17058234
41.

Gene silencing in the development of personalized cancer treatment: the targets, the agents and the delivery systems.

Verreault M, Webb MS, Ramsay EC, Bally MB.

Curr Gene Ther. 2006 Aug;6(4):505-33. Review.

PMID:
16918337
42.

The liver X-receptor alpha controls hepatic expression of the human bile acid-glucuronidating UGT1A3 enzyme in human cells and transgenic mice.

Verreault M, Senekeo-Effenberger K, Trottier J, Bonzo JA, Bélanger J, Kaeding J, Staels B, Caron P, Tukey RH, Barbier O.

Hepatology. 2006 Aug;44(2):368-78.

PMID:
16871576
43.

Enzymatic production of bile Acid glucuronides used as analytical standards for liquid chromatography-mass spectrometry analyses.

Caron P, Trottier J, Verreault M, Bélanger J, Kaeding J, Barbier O.

Mol Pharm. 2006 May-Jun;3(3):293-302.

PMID:
16749861
44.

Coordinate regulation of hepatic bile acid oxidation and conjugation by nuclear receptors.

Trottier J, Milkiewicz P, Kaeding J, Verreault M, Barbier O.

Mol Pharm. 2006 May-Jun;3(3):212-22. Review.

PMID:
16749854
45.

Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.

Edwards LA, Verreault M, Thiessen B, Dragowska WH, Hu Y, Yeung JH, Dedhar S, Bally MB.

Mol Cancer Ther. 2006 Mar;5(3):645-54.

46.

Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus.

Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y.

Neuropharmacology. 2005;49 Suppl 1:57-69.

PMID:
15993439
47.

Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.

Battistini B, Verreault M, Ayach B, Blouin A, Cernacek P, Jeng AY, Wessale J, Opgenorth T, Tsang J.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S386-9.

PMID:
15838327
48.

Fluctuations in spatial recognition memory across the menstrual cycle in female rhesus monkeys.

Lacreuse A, Verreault M, Herndon JG.

Psychoneuroendocrinology. 2001 Aug;26(6):623-39.

PMID:
11403982
49.

[Anomalies detected by radiography].

Duquette P, Michaud M, Laflamme L, Beaudoin J, Desrochers M, Turcotte C, Verreault M.

J Dent Que. 1985 Sep;22:407-17. French. No abstract available.

PMID:
3864812

Supplemental Content

Loading ...
Support Center